MX2023001702A - Dosificacion y administracion de anticuerpos anti-c5 para el tratamiento de la microangiopatia trombotica asociada al trasplante de celulas madre hematopoyeticas (hsct-tma). - Google Patents
Dosificacion y administracion de anticuerpos anti-c5 para el tratamiento de la microangiopatia trombotica asociada al trasplante de celulas madre hematopoyeticas (hsct-tma).Info
- Publication number
- MX2023001702A MX2023001702A MX2023001702A MX2023001702A MX2023001702A MX 2023001702 A MX2023001702 A MX 2023001702A MX 2023001702 A MX2023001702 A MX 2023001702A MX 2023001702 A MX2023001702 A MX 2023001702A MX 2023001702 A MX2023001702 A MX 2023001702A
- Authority
- MX
- Mexico
- Prior art keywords
- hsct
- tma
- stem cell
- hematopoietic stem
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Dermatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063065107P | 2020-08-13 | 2020-08-13 | |
| PCT/US2021/045823 WO2022036151A1 (en) | 2020-08-13 | 2021-08-12 | Dosage and administration of anti-c5 antibodies for treating hematopoietic stem cell transplant-associated thrombotic microangiopathy (hsct-tma) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023001702A true MX2023001702A (es) | 2023-03-09 |
Family
ID=77655658
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023001702A MX2023001702A (es) | 2020-08-13 | 2021-08-12 | Dosificacion y administracion de anticuerpos anti-c5 para el tratamiento de la microangiopatia trombotica asociada al trasplante de celulas madre hematopoyeticas (hsct-tma). |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240209071A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4196161A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7821160B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230047179A (cg-RX-API-DMAC7.html) |
| CN (1) | CN116249550A (cg-RX-API-DMAC7.html) |
| AU (2) | AU2021326526B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3173007A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL300115A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023001702A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022036151A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202426048A (zh) | 2022-09-06 | 2024-07-01 | 美商阿雷希昂製藥公司 | 用於治療造血幹細胞移植相關血栓性(hsct-tma)的抗c5抗體的補充劑量和投與 |
| CA3266977A1 (en) | 2022-09-06 | 2024-03-14 | Alexion Pharmaceuticals, Inc. | DIAGNOSTIC AND PROGNOSIS BIOMARKER PROFILES IN PATIENTS WITH HEMATOPOIETIC STEM CELL TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY (HSCT-TMA) |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| PY09026846A (es) | 2008-08-05 | 2015-09-01 | Novartis Ag | Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c5 |
| ES2796078T3 (es) * | 2013-09-16 | 2020-11-25 | Childrens Hospital Med Ct | Composiciones y métodos para el tratamiento de la microangiopatía trombótica asociada al hsct |
| NZ711451A (en) * | 2014-03-07 | 2016-05-27 | Alexion Pharma Inc | Anti-c5 antibodies having improved pharmacokinetics |
| EA201791366A1 (ru) | 2014-12-19 | 2018-02-28 | Чугаи Сейяку Кабусики Кайся | Антитела к c5 и способы их применения |
| CA3024618A1 (en) * | 2016-05-27 | 2017-11-30 | Alexion Pharmaceuticals, Inc. | Methods for treatment of refractory generalized myasthenia gravis |
| IL263481B2 (en) | 2016-06-14 | 2024-06-01 | Regeneron Pharma | Anti-c5 antibodies and uses thereof |
| JP7518764B2 (ja) * | 2017-10-26 | 2024-07-18 | アレクシオン ファーマシューティカルズ, インコーポレイテッド | 発作性夜間ヘモグロビン尿症(PNH)および非典型溶血性尿毒症症候群(aHUS)の処置のための抗C5抗体の投薬量および投与 |
| EP3802603A1 (en) * | 2018-06-04 | 2021-04-14 | Alexion Pharmaceuticals, Inc. | Dosage and administration of anti-c5 antibodies for treatment of atypical hemolytic uremic syndrome (ahus) in pediatric patients |
| US20230416344A1 (en) * | 2020-04-16 | 2023-12-28 | Alexion Pharmaceuticals, Inc. | Methods for treating a complement mediated disorder caused by viruses |
-
2021
- 2021-08-12 JP JP2023509698A patent/JP7821160B2/ja active Active
- 2021-08-12 US US18/018,936 patent/US20240209071A1/en active Pending
- 2021-08-12 MX MX2023001702A patent/MX2023001702A/es unknown
- 2021-08-12 IL IL300115A patent/IL300115A/en unknown
- 2021-08-12 WO PCT/US2021/045823 patent/WO2022036151A1/en not_active Ceased
- 2021-08-12 AU AU2021326526A patent/AU2021326526B2/en active Active
- 2021-08-12 CA CA3173007A patent/CA3173007A1/en active Pending
- 2021-08-12 CN CN202180050198.2A patent/CN116249550A/zh active Pending
- 2021-08-12 EP EP21766299.8A patent/EP4196161A1/en active Pending
- 2021-08-12 KR KR1020237008325A patent/KR20230047179A/ko active Pending
-
2025
- 2025-11-26 JP JP2025204019A patent/JP2026026191A/ja active Pending
-
2026
- 2026-03-11 AU AU2026201836A patent/AU2026201836A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP7821160B2 (ja) | 2026-02-26 |
| CA3173007A1 (en) | 2022-02-17 |
| CN116249550A (zh) | 2023-06-09 |
| EP4196161A1 (en) | 2023-06-21 |
| JP2023539047A (ja) | 2023-09-13 |
| KR20230047179A (ko) | 2023-04-06 |
| AU2021326526A1 (en) | 2023-03-02 |
| WO2022036151A1 (en) | 2022-02-17 |
| JP2026026191A (ja) | 2026-02-16 |
| US20240209071A1 (en) | 2024-06-27 |
| AU2026201836A1 (en) | 2026-05-21 |
| AU2021326526B2 (en) | 2025-12-11 |
| IL300115A (en) | 2023-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4424324A3 (en) | Dosage and administration of anti-c5 antibodies for treatment of patients with membranoproliferative glomerulonephritis | |
| MX2020008882A (es) | Dosificación para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1. | |
| PH12020550860A1 (en) | Anti-trem2 antibodies and related methods | |
| BR112019008010A2 (pt) | anticorpo monoclonal isolado ou fragmento imunologicamente ativo do mesmo, anticorpo monoclonal biespecífico isolado, composição farmacêutica, método para tratamento de uma doença em um sujeito humano em necessidade do mesmo, proteína de fusão, epítopo imunodominante codificado pelo gene cd47, e, molécula biológica | |
| PH12021500031A1 (en) | Anti-il2 receptor gamma antigen-binding proteins | |
| MX2020006171A (es) | Terapia de combinacion con anticuerpos anti interleucina-8 (il-8) y anticuerpos anti receptor de muerte programada (pd-1) para tratar cancer. | |
| PH12022553106A1 (en) | Sars-cov-2-antibodies and methods of selecting and using the same | |
| MX2025007897A (es) | Dosis y administracion de anticuerpos anti-c5 para el tratamiento de la hemoglobinuria paroxistica nocturna (hpn) y el sindrome hemolitico uremico atipico (shua) | |
| MX2024013016A (es) | Anticuerpos anti-pd1 para usarse en el tratamiento del cancer | |
| WO2007092939A8 (en) | Antigenic gm-csf peptides and antibodies to gm-csf | |
| NZ599971A (en) | Monoclonal antibodies to progastrin and their uses | |
| MX2022005249A (es) | Anticuerpos anti-cd45 y conjugados de los mismos. | |
| MX2023002541A (es) | Anticuerpo biespecifico contra el cumulo de diferenciacion 3 (cd3) y el cumulo de diferenciacion 20 (cd20) en terapia combinada para el tratamiento del linfoma difuso de celulas b grandes. | |
| EA202091974A1 (ru) | Связывающие bcma антитела и их применение | |
| MX2023002106A (es) | Anticuerpos fgfr3 y metodos de uso. | |
| MX2025004652A (es) | Conjugados de farmaco-anticuerpo del cumulo de diferenciacion (cd70) y metodos de uso de los mismos | |
| MX2023015073A (es) | Dosificacion y administracion de anticuerpos anti-c5 para el tratamiento de la dermatomiositis (dm). | |
| MX2023004806A (es) | Anticuerpos anti-tnf-a vectorizados para indicaciones oculares. | |
| BR112021015479A2 (pt) | Anticorpos anti-trem1 e métodos relacionados | |
| WO2024173376A3 (en) | Combination therapy comprising multispecific gamma delta tcr antibodies | |
| MX2025012203A (es) | Formulaciones farmaceuticas que contienen anticuerpos anti-ox40l | |
| MX2022006148A (es) | Metodos para tratamiento del cancer usando anticuerpos anti-ox40 en combinacion con anticuerpos anti-tigit. | |
| BR112023026111A2 (pt) | Anticorpo anti-cd40, fragmento de ligação ao antígeno e uso médico do mesmo | |
| WO2021062085A8 (en) | Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies | |
| BR112021024328A2 (pt) | Métodos e composições para tratar doenças autoimunes |